Essity SWOT Analysis
Dive Deeper Into the Company’s Strategic Blueprint
Essity’s SWOT highlights resilient global brands and strong hygiene-product demand, but also exposure to raw-material cost swings and emerging-market competition; strategic moves in sustainability and M&A could unlock growth. Purchase the full SWOT analysis to access a detailed, editable report with financial context, strategic recommendations, and an Excel matrix—ready for investor decks, planning, or due diligence.
Strengths
Market Leadership in Incontinence Products
Essity holds the global number one position in incontinence products via TENA, with the category contributing about 18% of group sales (≈SEK 28.5bn in 2025) and showing stable low-single-digit volume growth from aging demographics.
Essential demand and strong brand loyalty yield recurring revenue and lower churn among elderly care channels, where TENA has >30% market share in key European markets.
By end-2025 Essity’s medical-grade product focus supported higher gross margins—roughly 6 percentage points above its consumer tissue segment—helping sustain operating margin resilience.
Dominant Professional Hygiene Ecosystem
The Tork brand lets Essity dominate professional hygiene with a full dispenser-and-refill system, securing ~30% share in global away-from-home tissue (Essity FY2024: net sales SEK 139.6bn; Hygiene & Health ~SEK 90bn) and driving predictable B2B revenue.
High switching costs from integrated hardware, service contracts, and consumables lock clients—offices, hospitals, restaurants—boosting recurring margins and retention.
Adding digital cleaning software raised perceived value; Essity reported double-digit growth in connected-service sales in 2024, shifting revenue mix toward services vs pure product supply.
Robust Sustainability and Circularity Initiatives
Diversified Geographic Footprint and Local Production
Essity sells in about 150 countries, softening revenue exposure to single-market slumps; in 2024 geographic sales split showed roughly 40% Europe, 35% North America & Latin America, 25% APAC and others (FY2024 sales SEK 137.6bn).
Local production in ~100+ plants cuts freight spend and exposure to port slowdowns; shorter routes improve gross margin and reduced lead times.
Proximity lets Essity pivot product mixes quickly to local tastes, supporting stable market share and supply resilience during 2022–24 global logistics shocks.
- 150 countries served
- ~100 production plants
- FY2024 sales SEK 137.6bn
- Faster response, lower logistics risk
Strong Premium Brand Equity
Essity’s portfolio includes high-recognition brands like Libero, Lotus, and Cushelle, which in 2024 supported a price/mix gain contributing to the company’s 5.8% net sales growth to SEK 140.7bn, enabling premium pricing in tissue and baby care.
Persistent R&D investment yields product differentiation—better softness, strength, and skin-health claims—driving higher margins; Essity’s 2024 adjusted EBIT margin was 12.4%.
Strong brand equity lets Essity pass through portions of input-cost inflation, protecting profitability during 2022–24 pulp and energy price volatility.
- Brands: Libero, Lotus, Cushelle
- 2024 net sales: SEK 140.7bn
- 2024 adj. EBIT margin: 12.4%
- Price/mix positive vs. volume pressure
Essity: Global incontinence leader with premium brands, 12.4% EBIT and 110k tCO2e savings
Essity leads global incontinence (TENA ~18% group sales ≈SEK 28.5bn in 2025), strong B2B position (Tork ~30% away-from-home), wide footprint (150 countries, ~100 plants), premium brands (Libero, Lotus, Cushelle) and higher-margin medical products (adj. EBIT margin 12.4% in 2024); sustainability cuts raw-pulp use ~12% and saves ~110,000 tCO2e annually, supporting price/mix gains.
| Metric | Value (2024–25) |
|---|---|
| Group sales | SEK 140.7bn (2024) |
| TENA sales | ≈SEK 28.5bn (2025) |
| Adj. EBIT margin | 12.4% (2024) |
| Plants / Countries | ~100 / 150 |
| CO2 saved | ~110,000 tCO2e p.a. |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of Essity, highlighting its operational strengths, internal weaknesses, external growth opportunities, and market threats to assess strategic positioning and future risks.
Customizable Excel Spreadsheet
Provides a concise Essity SWOT snapshot for rapid strategic alignment, ideal for executives and teams needing a clear, visual summary of strengths, weaknesses, opportunities, and threats.
Weaknesses
Sensitivity to Volatile Pulp and Raw Material Costs
A large share of Essity’s cost base is tied to wood pulp, which rose ~22% y/y in 2024 with benchmark NBSK averaging about $850/ton in Q3 2024, exposing the company to sharp input swings. Pulp spikes compress margins because Essity typically lags in passing costs to retail—gross margin fell 120 bps in FY 2024 when pulp surged—making quarterly EPS volatile and driven by commodity moves outside management control.
Lower Margins in Consumer Tissue
The Consumer Tissue segment posts significantly lower margins—around 6–8% operating margin in 2024 versus ~15–18% for Personal Care—due to intense price competition and commodity-like products such as toilet paper and paper towels.
Even after restructuring that cut costs by SEK ~1.2bn in 2023, Tissue still drags group ROCE; Consumer Tissue ROCE was ~5% in 2024 versus group ROCE ~12%.
Significant Revenue Concentration in Europe
While Essity AB (publ) is global, about 62% of net sales in 2024 came from Europe, making the region its largest revenue source and driving roughly two-thirds of operating profit; that concentration raises exposure to Europe’s 2024 GDP growth of 0.7% and slow demographic trends.
High Capital Expenditure for Digital Transformation
Modernizing Essity’s legacy plants and building digital sales platforms needs large, ongoing capex—Essity spent SEK 5.0bn on operating investments in 2024, squeezing near-term cash flow versus digital-native rivals.
The Industry 4.0 shift to automation and smart logistics is multi-year and costly; estimated additional capex of SEK 3–6bn over 3 years would be material to margins and liquidity.
- SEK 5.0bn operating investments in 2024
- Projected SEK 3–6bn extra capex next 3 years
- Short-term cash strain vs agile startups
Structural Complexity of Global Supply Chains
Managing over 70 production sites and a product mix spanning hygiene, medical, and tissue increases Essity’s organizational complexity, contributing to slower decision cycles and ~8% higher SG&A per revenue compared with focused peers in 2024.
Harmonizing standards across ~150 markets raises compliance costs and operational friction; the management team reports multi-year programs to align quality and IT platforms, delaying full synergy realization.
- 70+ production sites
- 150 markets, diverse product lines
- ~8% higher SG&A/revenue vs peers (2024)
- Multi-year harmonization programs
Essity margin squeeze: high pulp costs, heavy Europe exposure, capex strains ROCE
Essity faces volatile input costs—NBSK pulp averaged ~$850/ton in Q3 2024, driving a 120 bp gross margin hit in FY2024 and EPS swings; Consumer Tissue margins lag (~6–8% vs 15–18% for Personal Care) and depress group ROCE (~5% vs ~12% in 2024). High Europe exposure (62% sales 2024), 70+ sites, 150 markets, SEK 5.0bn capex in 2024 and projected SEK 3–6bn additional capex over 3 years strain liquidity and raise SG&A ~8% vs peers.
| Metric | 2024 |
|---|---|
| Pulp NBSK (Q3 avg) | $850/ton |
| Gross margin hit | -120 bps FY2024 |
| Consumer Tissue op. margin | 6–8% |
| Group ROCE | ~12% |
| Consumer Tissue ROCE | ~5% |
| Europe share of sales | 62% |
| Capex | SEK 5.0bn (2024) |
| Projected extra capex | SEK 3–6bn (3 yrs) |
| Production sites | 70+ |
| Markets | 150 |
| SG&A vs peers | +8% |
What You See Is What You Get
Essity SWOT Analysis
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the complete, editable version is unlocked after payment.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Dive Deeper Into the Company’s Strategic Blueprint
Essity’s SWOT highlights resilient global brands and strong hygiene-product demand, but also exposure to raw-material cost swings and emerging-market competition; strategic moves in sustainability and M&A could unlock growth. Purchase the full SWOT analysis to access a detailed, editable report with financial context, strategic recommendations, and an Excel matrix—ready for investor decks, planning, or due diligence.
Strengths
Market Leadership in Incontinence Products
Essity holds the global number one position in incontinence products via TENA, with the category contributing about 18% of group sales (≈SEK 28.5bn in 2025) and showing stable low-single-digit volume growth from aging demographics.
Essential demand and strong brand loyalty yield recurring revenue and lower churn among elderly care channels, where TENA has >30% market share in key European markets.
By end-2025 Essity’s medical-grade product focus supported higher gross margins—roughly 6 percentage points above its consumer tissue segment—helping sustain operating margin resilience.
Dominant Professional Hygiene Ecosystem
The Tork brand lets Essity dominate professional hygiene with a full dispenser-and-refill system, securing ~30% share in global away-from-home tissue (Essity FY2024: net sales SEK 139.6bn; Hygiene & Health ~SEK 90bn) and driving predictable B2B revenue.
High switching costs from integrated hardware, service contracts, and consumables lock clients—offices, hospitals, restaurants—boosting recurring margins and retention.
Adding digital cleaning software raised perceived value; Essity reported double-digit growth in connected-service sales in 2024, shifting revenue mix toward services vs pure product supply.
Robust Sustainability and Circularity Initiatives
Diversified Geographic Footprint and Local Production
Essity sells in about 150 countries, softening revenue exposure to single-market slumps; in 2024 geographic sales split showed roughly 40% Europe, 35% North America & Latin America, 25% APAC and others (FY2024 sales SEK 137.6bn).
Local production in ~100+ plants cuts freight spend and exposure to port slowdowns; shorter routes improve gross margin and reduced lead times.
Proximity lets Essity pivot product mixes quickly to local tastes, supporting stable market share and supply resilience during 2022–24 global logistics shocks.
- 150 countries served
- ~100 production plants
- FY2024 sales SEK 137.6bn
- Faster response, lower logistics risk
Strong Premium Brand Equity
Essity’s portfolio includes high-recognition brands like Libero, Lotus, and Cushelle, which in 2024 supported a price/mix gain contributing to the company’s 5.8% net sales growth to SEK 140.7bn, enabling premium pricing in tissue and baby care.
Persistent R&D investment yields product differentiation—better softness, strength, and skin-health claims—driving higher margins; Essity’s 2024 adjusted EBIT margin was 12.4%.
Strong brand equity lets Essity pass through portions of input-cost inflation, protecting profitability during 2022–24 pulp and energy price volatility.
- Brands: Libero, Lotus, Cushelle
- 2024 net sales: SEK 140.7bn
- 2024 adj. EBIT margin: 12.4%
- Price/mix positive vs. volume pressure
Essity: Global incontinence leader with premium brands, 12.4% EBIT and 110k tCO2e savings
Essity leads global incontinence (TENA ~18% group sales ≈SEK 28.5bn in 2025), strong B2B position (Tork ~30% away-from-home), wide footprint (150 countries, ~100 plants), premium brands (Libero, Lotus, Cushelle) and higher-margin medical products (adj. EBIT margin 12.4% in 2024); sustainability cuts raw-pulp use ~12% and saves ~110,000 tCO2e annually, supporting price/mix gains.
| Metric | Value (2024–25) |
|---|---|
| Group sales | SEK 140.7bn (2024) |
| TENA sales | ≈SEK 28.5bn (2025) |
| Adj. EBIT margin | 12.4% (2024) |
| Plants / Countries | ~100 / 150 |
| CO2 saved | ~110,000 tCO2e p.a. |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of Essity, highlighting its operational strengths, internal weaknesses, external growth opportunities, and market threats to assess strategic positioning and future risks.
Customizable Excel Spreadsheet
Provides a concise Essity SWOT snapshot for rapid strategic alignment, ideal for executives and teams needing a clear, visual summary of strengths, weaknesses, opportunities, and threats.
Weaknesses
Sensitivity to Volatile Pulp and Raw Material Costs
A large share of Essity’s cost base is tied to wood pulp, which rose ~22% y/y in 2024 with benchmark NBSK averaging about $850/ton in Q3 2024, exposing the company to sharp input swings. Pulp spikes compress margins because Essity typically lags in passing costs to retail—gross margin fell 120 bps in FY 2024 when pulp surged—making quarterly EPS volatile and driven by commodity moves outside management control.
Lower Margins in Consumer Tissue
The Consumer Tissue segment posts significantly lower margins—around 6–8% operating margin in 2024 versus ~15–18% for Personal Care—due to intense price competition and commodity-like products such as toilet paper and paper towels.
Even after restructuring that cut costs by SEK ~1.2bn in 2023, Tissue still drags group ROCE; Consumer Tissue ROCE was ~5% in 2024 versus group ROCE ~12%.
Significant Revenue Concentration in Europe
While Essity AB (publ) is global, about 62% of net sales in 2024 came from Europe, making the region its largest revenue source and driving roughly two-thirds of operating profit; that concentration raises exposure to Europe’s 2024 GDP growth of 0.7% and slow demographic trends.
High Capital Expenditure for Digital Transformation
Modernizing Essity’s legacy plants and building digital sales platforms needs large, ongoing capex—Essity spent SEK 5.0bn on operating investments in 2024, squeezing near-term cash flow versus digital-native rivals.
The Industry 4.0 shift to automation and smart logistics is multi-year and costly; estimated additional capex of SEK 3–6bn over 3 years would be material to margins and liquidity.
- SEK 5.0bn operating investments in 2024
- Projected SEK 3–6bn extra capex next 3 years
- Short-term cash strain vs agile startups
Structural Complexity of Global Supply Chains
Managing over 70 production sites and a product mix spanning hygiene, medical, and tissue increases Essity’s organizational complexity, contributing to slower decision cycles and ~8% higher SG&A per revenue compared with focused peers in 2024.
Harmonizing standards across ~150 markets raises compliance costs and operational friction; the management team reports multi-year programs to align quality and IT platforms, delaying full synergy realization.
- 70+ production sites
- 150 markets, diverse product lines
- ~8% higher SG&A/revenue vs peers (2024)
- Multi-year harmonization programs
Essity margin squeeze: high pulp costs, heavy Europe exposure, capex strains ROCE
Essity faces volatile input costs—NBSK pulp averaged ~$850/ton in Q3 2024, driving a 120 bp gross margin hit in FY2024 and EPS swings; Consumer Tissue margins lag (~6–8% vs 15–18% for Personal Care) and depress group ROCE (~5% vs ~12% in 2024). High Europe exposure (62% sales 2024), 70+ sites, 150 markets, SEK 5.0bn capex in 2024 and projected SEK 3–6bn additional capex over 3 years strain liquidity and raise SG&A ~8% vs peers.
| Metric | 2024 |
|---|---|
| Pulp NBSK (Q3 avg) | $850/ton |
| Gross margin hit | -120 bps FY2024 |
| Consumer Tissue op. margin | 6–8% |
| Group ROCE | ~12% |
| Consumer Tissue ROCE | ~5% |
| Europe share of sales | 62% |
| Capex | SEK 5.0bn (2024) |
| Projected extra capex | SEK 3–6bn (3 yrs) |
| Production sites | 70+ |
| Markets | 150 |
| SG&A vs peers | +8% |
What You See Is What You Get
Essity SWOT Analysis
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the complete, editable version is unlocked after payment.
